

Enhancement of Binding Affinity of Folate to Its Receptor by Peptide Conjugation

Roopa Dharmatti ^{1,2}, Hideyuki Miyatake ^{1,*}, Avanashiappan Nandakumar ³, Motoki Ueda ^{1,3}, Kenya Kobayashi ¹, Daisuke Kiga ^{2,4}, Masayuki Yamamura ² and Yoshihiro Ito ^{1,2,3,*}

¹ Nano Medical Engineering Laboratory, RIKEN Cluster for Pioneering Research, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan; roopa.dharmatti@riken.jp (R.D.), motoki.ueda@riken.jp (M.U.), kenya.kobayashi@alpsalpine.com (K.K.)

² Department of Computer Science, School of Computing, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan, my@c.titech.ac.jp (M.Y.)

³ Emergent Bioengineering Materials Research Team, RIKEN Center for Emergent Matter Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan; nandakumar.avanashippan@riken.jp (A. N.)

⁴ Department of Electrical Engineering and Bioscience, Waseda University, 2-2 Wakamatsu Cho, Shinjuku-ku, Tokyo, 162-8480, Japan; kiga@waseda.jp (D.K.)

* Correspondence: miyatake@riken.jp (H.M.), y-ito@riken.jp (Y.I.); Tel. : +81-48-467-4979 (Y. I.), Fax: +81-48-467-9300 (Y. I.)

1. Synthesis of folate derivatives (compounds 9 and 16)




Figure S1. A ^1H NMR spectrum of folate-propargyl (compound 9).




Figure S2A. A ¹H NMR spectrum of folate-DBCO (compound 16).




Figure S2B. A ¹³C NMR spectrum of folate-DBCO (compound 16).




Figure S2C. HRMS of compound 16 (folate-DBCO).

2. Purification of peptides with the N-terminal modification by biotin-PEG₂₄ and after folate conjugation by SPAAC.




Figure S3. HPLC elution pattern of (A) GFZIQ, (B) SEZKA and (C) DSEZKAY.




Figure S4A. MALDI-TOF MS analysis of GFZIQ.




Figure S4B. MALDI-TOF MS analysis of SEZKA.




Figure S4C. MALDI-TOF MS analysis of DSEZKAY.

Table S1. MALDI-TOF MS results.

Peptide Sequences ^a	Molecular Mass (Da)	
	Calculated [M+H] ⁺	Observed [M+H] ⁺
GF ^a ZIQ	2705.3	2705.2
SEZKA	2675.3	2675.4
DSEZKAY	2953.4	2953.6

^aZ = folate conjugated AzPhe.

3. Purification and refolding of FR α .




Figure S5. Purification of FR α . (A) FPLC chromatogram of FR α recorded at 280 nm during the immobilized metal affinity chromatography (IMAC) purification procedure. (B) Quality analysis of FR α during each step of purification by 20% SDS-PAGE: M: Molecular mass marker; Lane 1: supernatant; Lane 2: pellet; Lane 3: solubilized inclusion body; Lane 4: FPLC Peak 1 (fractions 7–13); Lane 5 FPLC Peak 2 (fractions 14–30); Lane 6: FPLC Peak 3 (fractions 31–48); Lane 7: FR α in refolding buffer; Lane 8: refolded FR α ; Lane 9: precipitate during refolding.

Table S2. Purification steps and buffers.

Steps	Solution contents
Washing of inclusion body	<ul style="list-style-type: none"> • Sonication buffer: 50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, ,4 M urea, pH 7.5, 0.2 mg/mL lysozyme, 0.8 mg/mL DNase I • Washing buffer A: 50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 4 M urea, pH 7.5 • Washing buffer B: 50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 7.5
Solubilization of inclusion body proteins	<ul style="list-style-type: none"> • Solubilization buffer: 50 mM Tris-HCl, 8 M urea, 100 mM NaH₂PO₄, pH 8.0, 10 mM 2-mercaptoethanol

Steps	Solution contents
IMAC purification	<ul style="list-style-type: none"> • Binding buffer: 50 mM Tris-HCl, 8 M urea, 100 mM NaH₂PO₄, pH 8.0, 5 mM 2-mercaptoethanol • Elution buffer: 50 mM Tris-HCl, 8 M urea, 100 mM NaH₂PO₄, 1 M imidazole, pH 8.0, 5 mM 2-mercaptoethanol
Infinite dilution for refolding	<ul style="list-style-type: none"> • Refolding buffer: 50 mM Tris-HCl, 200 mM NaCl, pH 8.0, 1 mM EDTA, 1 mM GSSG, 5 mM GSH, 1 M L-arginine, 10% (v/v) glycerol, pH 8.0
Final concentration	<ul style="list-style-type: none"> • Replacing buffer: 50 mM Tris-HCl, 10% (v/v) glycerol, pH 8.0

Table S3. Summary of the yields of individual steps in the solubilization, purification and refolding of recombinant FR α from inclusion bodies per 10g of *E. coli*.

Steps	FRα (mL)	FRα^a (mg/mL)	FRα (mg)	FRα (%)
Solubilization of inclusion bodies	80	1.93	154.22	100
Purification by IMAC				
Elute peak 1	10.5	0.31	3.27	2.12
Elute peak 2	25.5	1.33	33.99	22.04
Elute peak 3	27	0.11	2.93	1.90
Refolded protein	1050	0.04	44.2	28.66
Soluble protein recovered	0.1	3.58	0.358	0.23

^aThe FR α concentration was determined by measuring the absorbance at 280 nm and using the molar extinction coefficient of 78520 M⁻¹ cm⁻¹.